{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T23:06:45Z","timestamp":1717024005923},"reference-count":24,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Anti-infective Therapy"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1586\/eri.09.110","type":"journal-article","created":{"date-parts":[[2009,12,7]],"date-time":"2009-12-07T19:36:33Z","timestamp":1260214593000},"page":"1159-1163","source":"Crossref","is-referenced-by-count":6,"title":["The SWITCHMRK studies: substitution of lopinavir\/ritonavir with raltegravir in HIV-positive individuals"],"prefix":"10.1586","volume":"7","author":[{"given":"Jennifer","family":"Cocohoba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"CIT0001","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","volume":"338","author":"Palella","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"CIT0002","unstructured":"WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. WHO Press, Geneva, Switzerland (2006)."},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1001\/jama.300.5.555"},{"key":"CIT0004","unstructured":"Isentress (raltegravir), package insert. Merck (2009)."},{"key":"CIT0005","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.clinthera.2008.10.012","volume":"30","author":"Cocohoba","year":"2008","journal-title":"Clin. Ther."},{"key":"CIT0006","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","volume":"359","author":"Steigbigel","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"CIT0007","unstructured":"Lennox J, Dejesus E, Lazzarin Aet al.Subgroup analyses from STARTMRK, a Phase III Study of raltegravir-based vs efavirenz-based combination therapy in treatment-naive HIV-infected patients. Presented at:16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 8\u201311 February 2009."},{"key":"CIT0008","first-page":"1423","volume":"76","author":"Feingold","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"CIT0009","first-page":"559","volume":"76","author":"Hellerstein","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000233574.49220.de"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1086\/378131"},{"key":"CIT0012","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/01.CIR.104.3.257","volume":"104","author":"Stein","year":"2001","journal-title":"Circulation"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.7.700"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318042e204"},{"key":"CIT0015","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/jac\/dkm413","volume":"61","author":"Soriano","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"CIT0016","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/00002030-200111090-00017","volume":"15","author":"Wensing","year":"2001","journal-title":"AIDS"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200305230-00010"},{"key":"CIT0018","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","volume":"356","author":"Friis-Moller","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"CIT0019","unstructured":"Eron J, Andrade J, Zajdenverg Ret al.Switching from stable lopinavir\/ritonavir-based to raltegravir-based combination ART resulted in a superior lipid profile at week 12 but did not demonstrate non-inferior virologic efficacy at week 24. Presented at:16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 8\u201311 February 2009 (Abstract 70aLB)."},{"key":"CIT0020","doi-asserted-by":"crossref","unstructured":"Talbot A, Machouf N, Thomas Ret al.Retrospective analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 12 weeks in a Montreal Cohort. Presented at:XVII International AIDS Conference. Mexico City, Mexico, 3\u20138 August 2008.","DOI":"10.1097\/QAI.0b013e3181aa1398"},{"key":"CIT0021","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1086\/605674","volume":"49","author":"De Castro","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.9.2926-2932.2002"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.16.7462-7469.2001"},{"key":"CIT0024","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa0708978","volume":"359","author":"Cooper","year":"2008","journal-title":"N. Engl. J. Med."}],"container-title":["Expert Review of Anti-infective Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/eri.09.110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T09:10:51Z","timestamp":1558689051000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1586\/eri.09.110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":24,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,1,10]]},"published-print":{"date-parts":[[2009,12]]}},"alternative-id":["10.1586\/eri.09.110"],"URL":"https:\/\/doi.org\/10.1586\/eri.09.110","relation":{},"ISSN":["1478-7210","1744-8336"],"issn-type":[{"value":"1478-7210","type":"print"},{"value":"1744-8336","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}